Almac expanding personalized cancer vaccine production facilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Cancer vaccine, Almac, Personalized medicine

The Almac Group is doubling its Edinburgh-based footprint to help meet the growing demand for personalized cancer vaccines production.

The contract development and manufacturing organization (CDMO) is doubling the footprint of its Fleming Building in the science and business park Edinburgh Technopole.

The expanded facility – which will double in size to more than 15,000 square feet – will aid the company’s scale-up of personalized cancer vaccine activities.

The CDMO ​also is investing in new laboratories and office space to meet demand.

Alastair Hay, peptides account manager at Almac Sciences said, “Personalized cancer vaccines based on neo-antigenic peptides is an exciting new era for oncology, and our Technopole site already has the world’s first GMP-certified facility specifically for the production of these peptide vaccines for clinical trials.”

Almac is not providing any further comment at this time.

Nearly a quarter of the company’s current resources in Edinburgh are engaged in cancer vaccine production, Hay said. The new space will be dedicated to this area, providing a four-fold increase in the GMP manufacturing footprint.

Almac in August 2018 announced​ that it would begin offering GMP supply of neoantigen-derived peptides for use in individualized cancer vaccine production at its Scotland-based facility.

Hay told us at the time that the company decided to launch the service following “requests from numerous parties over the last few years regarding requirement for high throughput peptide manufacture for use in individualized cancer vaccines.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars